Is there a single person feeding La Lettre fake biotech takeover tips, or is this a group effort? The stock manipulation is brazen.
First, we learn all the $ABVX $LLY French Ministry speculation was fake, now today it's $SNY $OCUL
The story explains Sanofi's interest in "combination therapies" --> Dextenza + Dupixent? What the f--k? Dextenza is a tiny eye implant, Dupixent is an injectable. What are you combining?
The La Lettre story doesn't even mention Axpaxli or the upcoming SOL-1 ph3 study readout.
I think $OCUL is interesting and if SOL-1 hits, the company could be sold. In fact, I wrote that in early January given CEO Pravin Dugel's track record selling Iveric to Astellas.
But, please, look at how $OCUL traded at the end of Wednesday.